{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:18:24Z","timestamp":1762431504064},"reference-count":69,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMIR"],"published-print":{"date-parts":[[2020,5,28]]},"abstract":"<jats:sec><jats:title \/><jats:p>Prostate cancer is one of the most common cancers in men. This cancer is often associated with indolent tumors with little or no lethal potential. Some of the patients with aggressive prostate cancer have increased morbidity and early deaths. A major complication in advanced prostate cancer is bone metastasis that mainly results in pain, pathological fractures, and compression of spinal nerves. These complications in turn cause severe pain radiating to the extremities and possibly sensory as well as motor disturbances. Further, in patients with a high risk of metastases, treatment is limited to palliative therapies. Therefore, accurate methods for the detection of bone metastases are essential. Technical advances such as single-photon emission computed tomography\/ computed tomography (SPECT\/CT) have emerged after the introduction of bone scans. These advanced methods allow tomographic image acquisition and help in attenuation correction with anatomical co-localization. The use of positron emission tomography\/CT (PET\/CT) scanners is also on the rise. These PET scanners are mainly utilized with 18F-sodium-fluoride (NaF), in order to visualize the skeleton and possible changes. Moreover, NaF PET\/CT is associated with higher tracer uptake, increased target-to-background ratio and has a higher spatial resolution. However, these newer technologies have not been adopted in clinical guidelines due to lack of definite evidence in support of their use in bone metastases cases. The present review article is focused on current perspectives and challenges of computerized tomography (CT) applications in cases of bone metastases during prostate cancer.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573405614666181009144601","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T13:10:51Z","timestamp":1539263451000},"page":"565-571","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer"],"prefix":"10.2174","volume":"16","author":[{"given":"Jinguo","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiology, Dezhou People's Hospital, Dezhou, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanzhong","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Dezhou People's Hospital, Dezhou, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Dezhou People's Hospital, Dezhou, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhe","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Dezhou People's Hospital, Dezhou, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay J.","year":"2015","unstructured":"Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D.M.; Forman D.; Bray F.; Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015,136(5),E359-E386","journal-title":"Int J Cancer"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.23736\/S0393-2249.18.03182-X","volume":"70","author":"DE Nunzio C.","year":"2018","unstructured":"DE Nunzio C.; Presicce F.; Giacinti S.; Bassanelli M.; Tubaro A.; Castration-resistance prostate cancer: what is in the pipeline? Minerva Urol Nefrol 2018,70(1),22-41","journal-title":"Minerva Urol Nefrol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MOU.0000000000000460","volume":"28","author":"Ballon-Landa E.","year":"2018","unstructured":"Ballon-Landa E.; Parsons J.K.; Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Curr Opin Urol 2018,28(1),55-61","journal-title":"Curr Opin Urol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"Litwin M.S.","year":"2017","unstructured":"Litwin M.S.; Tan H.J.; The diagnosis and treatment of prostate cancer: a review. JAMA 2017,317(24),2532-2542","journal-title":"JAMA"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00261-016-0851-3","volume":"42","author":"Vargas H.A.","year":"2017","unstructured":"Vargas H.A.; Schor-Bardach R.; Long N.; Kirzner A.N.; Cunningham J.D.; Goldman D.A.; Moskowitz C.S.; Sosa R.E.; Sala E.; Panicek D.M.; Hricak H.; Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. Abdom Radiol (NY) 2017,42(1),271-277","journal-title":"Abdom Radiol (NY)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1754-9485.12407","volume":"60","author":"Daniels C.P.","year":"2016","unstructured":"Daniels C.P.; Millar J.L.; Spelman T.; Sengupta S.; Evans S.M.; Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the Prostate Cancer Registry. J Med Imaging Radiat Oncol 2016,60(2),247-254","journal-title":"J Med Imaging Radiat Oncol"},{"key":"ref=7","first-page":"231","volume":"71","author":"Mayor de Castro J.","year":"2018","unstructured":"Mayor de Castro J.; Ca\u00f1o Velasco J.; Arag\u00f3n Chamizo J.; Andr\u00e9s Boville G.; Herranz Amo F.; Hern\u00e1ndez F.C.; Locally advanced prostate cancer. Definition, diagnosis and treatment. Arch Esp Urol 2018,71(3),231-238","journal-title":"Arch Esp Urol"},{"key":"ref=8","first-page":"258","volume":"71","author":"Rosino-S\u00e1nchez A.","year":"2018","unstructured":"Rosino-S\u00e1nchez A.; [Preventive management of bone disease in advanced prostate cancer]. Arch Esp Urol 2018,71(3),258-266","journal-title":"Arch Esp Urol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1148\/rg.2018170147","volume":"38","author":"Patel P.","year":"2018","unstructured":"Patel P.; Mathew M.S.; Trilisky I.; Oto A.; Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics 2018,38(2),437-449","journal-title":"Radiographics"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-017-9719-4","volume":"37","author":"Logothetis C.","year":"2018","unstructured":"Logothetis C.; Morris M.J.; Den R.; Coleman R.E.; Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 2018,37(1),189-196","journal-title":"Cancer Metastasis Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00223-017-0350-8","volume":"102","author":"Park S.H.","year":"2018","unstructured":"Park S.H.; Keller E.T.; Shiozawa Y.; Bone marrow microenvironment as a regulator and Therapeutic target for prostate cancer bone metastasis. Calcif Tissue Int 2018,102(2),152-162","journal-title":"Calcif Tissue Int"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/1556-4029.13617","volume":"63","author":"Castoldi E.","year":"2018","unstructured":"Castoldi E.; Cappella A.; Gibelli D.; Sforza C.; Cattaneo C.; the difficult task of diagnosing prostate cancer metastases on dry bone. J Forensic Sci 2018,63(3),672-682","journal-title":"J Forensic Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"Bubendorf L.","year":"2000","unstructured":"Bubendorf L.; Sch\u00f6pfer A.; Wagner U.; Sauter G.; Moch H.; Willi N.; Gasser T.C.; Mihatsch M.J.; Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000,31(5),578-583","journal-title":"Hum Pathol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"N\u00f8rgaard M.","year":"2010","unstructured":"N\u00f8rgaard M.; Jensen A.O.; Jacobsen J.B.; Cetin K.; Fryzek J.P.; S\u00f8rensen H.T.; Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010,184(1),162-167","journal-title":"J Urol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RLU.0000000000000291","volume":"39","author":"Zacho H.D.","year":"2014","unstructured":"Zacho H.D.; Barsi T.; Mortensen J.C.; Mogensen M.K.; Bertelsen H.; Josephsen N.; Petersen L.J.; Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer. Clin Nucl Med 2014,39(1),26-31","journal-title":"Clin Nucl Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.urology.2016.09.019","volume":"99","author":"Zacho H.D.","year":"2017","unstructured":"Zacho H.D.; M\u00f8rch C.D.; Barsi T.; Mortensen J.C.; Bertelsen H.; Petersen L.J.; Unexplained bone pain is an independent risk factor for bone metastases in newly diagnosed prostate cancer: a prospective study. Urology 2017,99,148-154","journal-title":"Urology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2009.12.023","volume":"57","author":"Briganti A.","year":"2010","unstructured":"Briganti A.; Passoni N.; Ferrari M.; Capitanio U.; Suardi N.; Gallina A.; Da Pozzo L.F.; Picchio M.; Di Girolamo V.; Salonia A.; Gianolli L.; Messa C.; Rigatti P.; Montorsi F.; When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010,57(4),551-558","journal-title":"Eur Urol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/17453674.2017.1372097","volume":"89","author":"Bernhardsson M.","year":"2018","unstructured":"Bernhardsson M.; Sandberg O.; Ressner M.; Koziorowski J.; Malmquist J.; Aspenberg P.; Shining dead bone-cause for cautious interpretation of [F]NaF PET scans. Acta Orthop 2018,89(1),124-127","journal-title":"Acta Orthop"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.mri.2017.09.011","volume":"45","author":"Maggu J.","year":"2018","unstructured":"Maggu J.; Singh P.; Majumdar A.; Multi-echo reconstruction from partial K-space scans via adaptively learnt basis. Magn Reson Imaging 2018,45,105-112","journal-title":"Magn Reson Imaging"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/21681805.2015.1076031","volume":"50","author":"Zacho H.D.","year":"2016","unstructured":"Zacho H.D.; Barsi T.; Mortensen J.C.; Bertelsen H.; Petersen L.J.; Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy. Scand J Urol 2016,50(1),29-32","journal-title":"Scand J Urol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2012.42.8375","volume":"30","author":"Schnipper L.E.","year":"2012","unstructured":"Schnipper L.E.; Smith T.J.; Raghavan D.; Blayney D.W.; Ganz P.A.; Mulvey T.M.; Wollins D.S.; American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012,30(14),1715-1724","journal-title":"J Clin Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"Mohler J.L.","year":"2016","unstructured":"Mohler J.L.; Armstrong A.J.; Bahnson R.R.; D\u2019Amico A.V.; Davis B.J.; Eastham J.A.; Enke C.A.; Farrington T.A.; Higano C.S.; Horwitz E.M.; Hurwitz M.; Kane C.J.; Kawachi M.H.; Kuettel M.; Lee R.J.; Meeks J.J.; Penson D.F.; Plimack E.R.; Pow-Sang J.M.; Raben D.; Richey S.; Roach M.; Rosenfeld S.; Schaeffer E.; Skolarus T.A.; Small E.J.; Sonpavde G.; Srinivas S.; Strope S.A.; Tward J.; Shead D.A.; Freedman-Cass D.A.; Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw 2016,14(1),19-30","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","volume":"43","author":"Van den Wyngaert T.","year":"2016","unstructured":"Van den Wyngaert T.; Strobel K.; Kampen W.U.; Kuwert T.; van der Bruggen W.; Mohan H.K.; Gnanasegaran G.; Delgado-Bolton R.; Weber W.A.; Beheshti M.; Langsteger W.; Giammarile F.; Mottaghy F.M.; Paycha F.; The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging EANM Bone","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=24","first-page":"209","volume":"205","author":"Donohoe K.J.","year":"2003","unstructured":"Donohoe K.J.; Brown M.L.; Collier B.D.; Society of nuclear medicine procedure guideline for bone scintigraphy. Bone Scintigr 2003,205,209","journal-title":"Bone Scintigr"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/MNM.0000000000000822","volume":"39","author":"Lee J.W.","year":"2018","unstructured":"Lee J.W.; Lee S.W.; Chang S.H.; Lee S.M.; Clinical role of bone scintigraphy in low-to-intermediate Framingham risk patients with atypical chest pain. Nucl Med Commun 2018,39(5),411-416","journal-title":"Nucl Med Commun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2967\/jnmt.117.199315","volume":"46","author":"Kaur H.","year":"2018","unstructured":"Kaur H.; Muhleman M.; Balon H.R.; Hypertrophic osteoarthropathy on bone scintigraphy. J Nucl Med Technol 2018,46(2),147-148","journal-title":"J Nucl Med Technol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.crad.2017.08.004","volume":"73","author":"Suh C.H.","year":"2018","unstructured":"Suh C.H.; Shinagare A.B.; Westenfield A.M.; Ramaiya N.H.; Van den Abbeele A.D.; Kim K.W.; Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. Clin Radiol 2018,73(2),158-167","journal-title":"Clin Radiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.112.114298","volume":"54","author":"Wong K.K.","year":"2013","unstructured":"Wong K.K.; Piert M.; Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med 2013,54(4),590-599","journal-title":"J Nucl Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2967\/jnumed.110.082263","volume":"51","author":"Segall G.","year":"2010","unstructured":"Segall G.; Delbeke D.; Stabin M.G.; Even-Sapir E.; Fair J.; Sajdak R.; Smith G.T.; SNM practice guideline for sodium 18F-fluoride PET\/CT bone scans 1.0. J Nucl Med SNM2010,51(11),1813-1820","journal-title":"J Nucl Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00256-017-2807-2","volume":"47","author":"Kasalak \u00d6.","year":"2018","unstructured":"Kasalak \u00d6.; Glaudemans A.W.J.M.; Overbosch J.; Jutte P.C.; Kwee T.C.; Can FDG-PET\/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? Skeletal Radiol 2018,47(3),363-367","journal-title":"Skeletal Radiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/qims.2018.01.02","volume":"8","author":"Blake G.M.","year":"2018","unstructured":"Blake G.M.; Puri T.; Siddique M.; Frost M.L.; Moore A.E.B.; Fogelman I.; Site specific measurements of bone formation using [F] sodium fluoride PET\/CT. Quant Imaging Med Surg 2018,8(1),47-59","journal-title":"Quant Imaging Med Surg"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MPH.0000000000001135","volume":"40","author":"Ruggiero A.","year":"2018","unstructured":"Ruggiero A.; Lanni V.; Librizzi A.; Maurizi P.; Attin\u00e0 G.; Mastrangelo S.; Giordano A.; Riccardi R.; Diagnostic accuracy of 18F-FDG PET\/CT in the staging and assessment of response to chemotherapy in children with ewing sarcoma. J Pediatr Hematol Oncol 2018,40(4),277-284","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/jnumed.113.130005","volume":"55","author":"Hillner B.E.","year":"2014","unstructured":"Hillner B.E.; Siegel B.A.; Hanna L.; Duan F.; Shields A.F.; Coleman R.E.; Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med 2014,55(4),574-581","journal-title":"J Nucl Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41391-017-0007-8","volume":"21","author":"Li R.","year":"2018","unstructured":"Li R.; Ravizzini G.C.; Gorin M.A.; Maurer T.; Eiber M.; Cooperberg M.R.; Alemozzaffar M.; Tollefson M.K.; Delacroix S.E.; Chapin B.F.; The use of PET\/CT in prostate cancer. Prostate Cancer Prostatic Dis 2018,21(1),4-21","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874471010666171101121803","volume":"11","author":"Giovacchini G.","year":"2018","unstructured":"Giovacchini G.; Giovannini E.; Riondato M.; Ciarmiello A.; PET\/CT With 68Ga-PSMA in prostate cancer: radiopharmaceutical background and clinical implications. Curr Radiopharm 2018,11(1),4-13","journal-title":"Curr Radiopharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ucl.2018.03.007","volume":"45","author":"Castellucci P.","year":"2018","unstructured":"Castellucci P.; Ceci F.; Fanti S.; Imaging of prostate cancer using 11C-Choline PET\/computed tomography. Urol Clin North Am 2018,45(3),481-487","journal-title":"Urol Clin North Am"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"Hofman M.S.","year":"2018","unstructured":"Hofman M.S.; Hicks R.J.; Maurer T.; Eiber M.; Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018,38(1),200-217","journal-title":"Radiographics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","volume":"16","author":"Cook G.J.","year":"1998","unstructured":"Cook G.J.; Houston S.; Rubens R.; Maisey M.N.; Fogelman I.; Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998,16(10),3375-3379","journal-title":"J Clin Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s11604-013-0179-7","volume":"31","author":"Damle N.A.","year":"2013","unstructured":"Damle N.A.; Bal C.; Bandopadhyaya G.P.; Kumar L.; Kumar P.; Malhotra A.; Lata S.; The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET\/CT and 99mTc-MDP bone scan. Jpn J Radiol 2013,31(4),262-269","journal-title":"Jpn J Radiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11307-011-0486-2","volume":"14","author":"Iagaru A.","year":"2012","unstructured":"Iagaru A.; Mittra E.; Dick D.W.; Gambhir S.S.; Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET\/CT, and (18)F FDG PET\/CT for detection of skeletal metastases. Mol Imaging Biol 2012,14(2),252-259","journal-title":"Mol Imaging Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00259-016-3350-4","volume":"43","author":"Evangelista L.","year":"2016","unstructured":"Evangelista L.; Bertoldo F.; Boccardo F.; Conti G.; Menchi I.; Mungai F.; Ricardi U.; Bombardieri E.; Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging 2016,43(8),1546-1562","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/MNM.0b013e328364918a","volume":"34","author":"Wondergem M.","year":"2013","unstructured":"Wondergem M.; van der Zant F.M.; van der Ploeg T.; Knol R.J.; A literature review of 18F-fluoride PET\/CT and 18F-choline or 11C-choline PET\/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013,34(10),935-945","journal-title":"Nucl Med Commun"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","volume":"43","author":"Pyka T.","year":"2016","unstructured":"Pyka T.; Okamoto S.; Dahlbender M.; Tauber R.; Retz M.; Heck M.; Tamaki N.; Schwaiger M.; Maurer T.; Eiber M.; Comparison of bone scintigraphy and Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016,43(12),2114-2121","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=44","volume":"S1558-7673","author":"Lengana T","year":"2018","unstructured":"Lengana T; Lawal IO; Boshomane TG; 68Ga-PSMA PET\/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Clin Genitourin Cancer 2018,S1558-7673(18)","journal-title":"Clin Genitourin Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics8010009","volume":"8","author":"Petersen L.J.","year":"2018","unstructured":"Petersen L.J.; Strandberg J.; Stenholt L.; Johansen M.B.; Zacho H.D.; Reporting and handling of indeterminate bone scan results in the staging of prostate cancer: a systematic review. Diagnostics (Basel) 2018,8(1)","journal-title":"Diagnostics (Basel)"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/wjnm.WJNM_54_17","volume":"17","author":"Cuccurullo V.","year":"2018","unstructured":"Cuccurullo V.; Di Stasio G.D.; Mansi L.; Nuclear medicine in prostate cancer: a new era for radiotracers. World J Nucl Med 2018,17(2),70-78","journal-title":"World J Nucl Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/jbmr.3444","volume":"33","author":"Cook G.J.","year":"2018","unstructured":"Cook G.J.; Goh V.; Functional and hybrid imaging of bone metastases. J Bone Miner Res 2018,33(6),961-972","journal-title":"J Bone Miner Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00259-013-2532-6","volume":"41","author":"Palmedo H.","year":"2014","unstructured":"Palmedo H.; Marx C.; Ebert A.; Kreft B.; Ko Y.; T\u00fcrler A.; Vorreuther R.; G\u00f6hring U.; Schild H.H.; Gerhardt T.; P\u00f6ge U.; Ezziddin S.; Biersack H.J.; Ahmadzadehfar H.; Whole-body SPECT\/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 2014,41(1),59-67","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MNM.0b013e3283412ef5","volume":"32","author":"Withofs N.","year":"2011","unstructured":"Withofs N.; Grayet B.; Tancredi T.; Rorive A.; Mella C.; Giacomelli F.; Mievis F.; Aerts J.; Waltregny D.; Jerusalem G.; Hustinx R.; F-fluoride PET\/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011,32(3),168-176","journal-title":"Nucl Med Commun"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2214\/AJR.11.8351","volume":"199","author":"Mosavi F.","year":"2012","unstructured":"Mosavi F.; Johansson S.; Sandberg D.T.; Turesson I.; S\u00f6rensen J.; Ahlstr\u00f6m H.; Whole-body diffusion-weighted MRI compared with (18)F-NaF PET\/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 2012,199(5),1114-1120","journal-title":"AJR Am J Roentgenol"},{"key":"ref=51","first-page":"448","volume":"55","author":"Langsteger W.","year":"2011","unstructured":"Langsteger W.; Balogova S.; Huchet V.; Beheshti M.; Paycha F.; Egrot C.; Janetschek G.; Loidl W.; Nataf V.; Kerrou K.; Pascal O.; Cussenot O.; Talbot J.N.; Fluorocholine (18F) and sodium fluoride (18F) PET\/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011,55(4),448-457","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","volume":"55","author":"Jambor I.","year":"2016","unstructured":"Jambor I.; Kuisma A.; Ramadan S.; Huovinen R.; Sandell M.; Kajander S.; Kemppainen J.; Kauppila E.; Auren J.; Merisaari H.; Saunavaara J.; Noponen T.; Minn H.; Aronen H.J.; Sepp\u00e4nen M.; Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol 2016,55(1),59-67","journal-title":"Acta Oncol"},{"key":"ref=53","unstructured":"Oxford Centre for evidence-based medicine; OCEBM levels of evidence working group. The Oxford levels of evidence 2 Available at:","journal-title":"The Oxford levels of evidence 2"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1148\/radiol.14141160","volume":"274","author":"Korevaar D.A.","year":"2015","unstructured":"Korevaar D.A.; Wang J.; van Enst W.A.; Leeflang M.M.; Hooft L.; Smidt N.; Bossuyt P.M.; Reporting diagnostic accuracy studies: some improvements after 10 years of STARD. Radiology 2015,274(3),781-789","journal-title":"Radiology"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/bmj.i402","volume":"352","author":"Naaktgeboren C.A.","year":"2016","unstructured":"Naaktgeboren C.A.; de Groot J.A.; Rutjes A.W.; Bossuyt P.M.; Reitsma J.B.; Moons K.G.; Anticipating missing reference standard data when planning diagnostic accuracy studies. BMJ 2016,352,402-5","journal-title":"BMJ"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jclinepi.2009.02.005","volume":"62","author":"Reitsma J.B.","year":"2009","unstructured":"Reitsma J.B.; Rutjes A.W.; Khan K.S.; Coomarasamy A.; Bossuyt P.M.; A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol 2009,62(8),797-806","journal-title":"J Clin Epidemiol"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001531","volume":"10","author":"Bertens L.C.","year":"2013","unstructured":"Bertens L.C.; Broekhuizen B.D.; Naaktgeboren C.A.; Rutten F.H.; Hoes A.W.; van Mourik Y.; Moons K.G.; Reitsma J.B.; Use of expert panels to define the reference standard in diagnostic research: a systematic review of published methods and reporting. PLoS Med 2013,10(10)","journal-title":"PLoS Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1111\/bju.12589","volume":"114","author":"Sonpavde G.","year":"2014","unstructured":"Sonpavde G.; Pond G.R.; Armstrong A.J.; Galsky M.D.; Leopold L.; Wood B.A.; Wang S.L.; Paolini J.; Chen I.; Chow-Maneval E.; Mooney D.J.; Lechuga M.; Smith M.R.; Michaelson M.D.; Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int 2014,114(6b),E25-E31","journal-title":"BJU Int"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.21873\/anticanres.12705","volume":"38","author":"Ferda J.","year":"2018","unstructured":"Ferda J.; Ferdov\u00e1 E.; Baxa J.; F\u00ednek J.; Topol\u010dan O.; 18F-Fluorocholine PET\/MRI in restaging of prostatic carcinoma in relation to psa level and detection of active disease. Anticancer Res 2018,38(7),4139-4143","journal-title":"Anticancer Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","volume":"33","author":"Morris M.J.","year":"2015","unstructured":"Morris M.J.; Molina A.; Small E.J.; de Bono J.S.; Logothetis C.J.; Fizazi K.; de Souza P.; Kantoff P.W.; Higano C.S.; Li J.; Kheoh T.; Larson S.M.; Matheny S.L.; Naini V.; Burzykowski T.; Griffin T.W.; Scher H.I.; Ryan C.J.; Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 2015,33(12),1356-1363","journal-title":"J Clin Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/21681805.2014.982169","volume":"49","author":"Nome R.","year":"2015","unstructured":"Nome R.; Hernes E.; Bogsrud T.V.; Bj\u00f8ro T.; Foss\u00e5 S.D.; Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol 2015,49(3),211-217","journal-title":"Scand J Urol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13550-016-0173-z","volume":"6","author":"Anand A.","year":"2016","unstructured":"Anand A.; Morris M.J.; Larson S.M.; Minarik D.; Josefsson A.; Helgstrand J.T.; Oturai P.S.; Edenbrandt L.; R\u00f8der M.A.; Bjartell A.; Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res 2016,6(1),23","journal-title":"EJNMMI Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.urolonc.2014.08.006","volume":"32","author":"Armstrong A.J.","year":"2014","unstructured":"Armstrong A.J.; Kaboteh R.; Carducci M.A.; Damber J.E.; Stadler W.M.; Hansen M.; Edenbrandt L.; Forsberg G.; Nordle \u00d6.; Pili R.; Morris M.J.; Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014,32(8),1308-1316","journal-title":"Urol Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/2191-219X-3-64","volume":"3","author":"Kaboteh R.","year":"2013","unstructured":"Kaboteh R.; Gjertsson P.; Leek H.; Lomsky M.; Ohlsson M.; Sj\u00f6strand K.; Edenbrandt L.; Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res 2013,3(1),64","journal-title":"EJNMMI Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00259-008-0721-5","volume":"35","author":"Sadik M.","year":"2008","unstructured":"Sadik M.; Suurkula M.; H\u00f6glund P.; J\u00e4rund A.; Edenbrandt L.; Quality of planar whole-body bone scan interpretations--a nationwide survey. Eur J Nucl Med Mol Imaging 2008,35(8),1464-1472","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2967\/jnumed.115.160085","volume":"57","author":"Anand A.","year":"2016","unstructured":"Anand A.; Morris M.J.; Kaboteh R.; B\u00e5th L.; Sadik M.; Gjertsson P.; Lomsky M.; Edenbrandt L.; Minarik D.; Bjartell A.; Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate cancer. J Nucl Med 2016,57(1),41-45","journal-title":"J Nucl Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2191-219X-1-4","volume":"1","author":"Cook G.","year":"2011","unstructured":"Cook G.; Parker C.; Chua S.; Johnson B.; Aksnes A.K.; Lewington V.J.; 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011,1(1),4","journal-title":"EJNMMI Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"886","DOI":"10.2967\/jnumed.115.166512","volume":"57","author":"Apolo A.B.","year":"2016","unstructured":"Apolo A.B.; Lindenberg L.; Shih J.H.; Mena E.; Kim J.W.; Park J.C.; Alikhani A.; McKinney Y.Y.; Weaver J.; Turkbey B.; Parnes H.L.; Wood L.V.; Madan R.A.; Gulley J.L.; Dahut W.L.; Kurdziel K.A.; Choyke P.L.; Prospective study evaluating Na18F PET\/CT in predicting clinical outcomes and survival in advanced prostate cancer. J Nucl Med 2016,57(6),886-892","journal-title":"J Nucl Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/diagnostics5040413","volume":"5","author":"Kairemo K.","year":"2015","unstructured":"Kairemo K.; Joensuu T.; Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation using F-18-Fluoride PET\/CT. Diagnostics (Basel) 2015,5(4),413-427","journal-title":"Diagnostics (Basel)"}],"container-title":["Current Medical Imaging Formerly Current Medical Imaging Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/166097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T20:44:15Z","timestamp":1662237855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/166097\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573405614666181009144601","relation":{},"ISSN":["1573-4056"],"issn-type":[{"value":"1573-4056","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}